Johnson & Johnson Announces Submission of Emergency Use Authorization Amendment to the U.S. FDA to Support Booster of its Single-Shot COVID-19 Vaccine | Johnson & Johnson

Johnson & Johnson Announces Submission of Emergency Use Authorization Amendment to the U.S. FDA to Support Booster of its Single-Shot COVID-19 Vaccine

10/05/2021

DownloadPDF 141 KB

Multimedia Files:

Questions? Please contact us:

investor-relations@its.jnj.com